Source:http://linkedlifedata.com/resource/pubmed/id/10459572
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
1999-9-7
|
pubmed:abstractText |
Hyperhomocysteinemia is a condition caused by both genetic and nongenetic factors. To determine whether a common methylenetetrahydrofolate reductase (MTHFR) variant is related to elevated homocysteine concentrations in epileptic patients receiving anticonvulsants, we investigated the plasma total homocysteine (tHcy) level, folate level, and MTHFR 677 C --> T mutation using a polymerase chain reaction (PCR) and restriction fragment length polymorphism analysis with HinfI digestion in 103 patients with epilepsy and 103 normal controls. The prevalence of hyperhomocysteinemia (> or = 11.4 micromol/L, 90th percentile of control group) was higher in patients than in controls (25% v 10.0%, P = .007). The homozygosity for the 677 C --> T mutation of MTHFR was associated with elevated tHcy and low folate levels. The magnitude of hyperhomocysteinemia in MTHFR TT homozygotes was more pronounced in epileptic patients than in controls (18.2 +/- 1.6 v 9.1 +/- 1.2 micromol/L, P = .04). In epileptic patients, hyperhomocysteinemia was more frequent in MTHFR TT genotypes versus CT or CC genotypes (58% v 17% and 16%, P < .001). Multiple logistic regression analysis showed that MTHFR TT genotype was an independent predictor of hyperhomocysteinemia in epileptic patients receiving anticonvulsants (phenytoin and carbamazepine but not valproic acid), suggesting that gene-drug interactions induce hyperhomocysteinemia. These findings indicate that epileptic patients receiving anticonvulsants may have a higher folate requirement to maintain a normal tHcy level, especially homozygotes for MTHFR 677 C --> T mutation.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0026-0495
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
48
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1047-51
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10459572-Adolescent,
pubmed-meshheading:10459572-Adult,
pubmed-meshheading:10459572-Anticonvulsants,
pubmed-meshheading:10459572-Epilepsy,
pubmed-meshheading:10459572-Female,
pubmed-meshheading:10459572-Folic Acid,
pubmed-meshheading:10459572-Homozygote,
pubmed-meshheading:10459572-Humans,
pubmed-meshheading:10459572-Hyperhomocysteinemia,
pubmed-meshheading:10459572-Male,
pubmed-meshheading:10459572-Methylenetetrahydrofolate Reductase (NADPH2),
pubmed-meshheading:10459572-Oxidoreductases Acting on CH-NH Group Donors,
pubmed-meshheading:10459572-Point Mutation
|
pubmed:year |
1999
|
pubmed:articleTitle |
A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants.
|
pubmed:affiliation |
Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|